If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  DDW: Thalomid Active In Treating Crohn's Disease ORLANDO, FL -- May 19, 1999 -- Researchers investigating the use of Celgene Corp.’s Thalomid(R) (thalidomide) to treat Crohn's disease today announced preliminary findings from a pilot study which showed that the drug is active in treating the condition. The study was presented at the annual Digestive Disease Week meeting in Orlando, FL. Lead investigator, Eric Vasiliauskas, M.D., associate clinical director of the Inflammatory Bowel Disease Center at Cedar's Sinai, Los Angeles reported findings from a pilot study of 12 patients at the centre. All patients had chronic, steroid-dependent or unresponsive Crohn's disease, an inflammatory disease of the intestinal tract. According to Dr. Vasiliauskas, while all study participants felt better on the drug, two-thirds of the patients treated with Thalomid experienced a significant improvement in their condition. as measured by the Crohn's Disease Activity Index (CDAI). The most common side effects reported were drowsiness and transient peripheral neuropathy. "Although this was a pilot study, we did observe improvements in CDAI in these patients with Crohn's disease, which had been refractory to standard therapies," Dr. Vasiliauskas said. "In addition, these scores were maintained in most patients, even after steroids were tapered. Decreased fistula drainage and fistula closure was also observed in some patients. The data suggest that a phase III study using thalidomide to treat Crohn's disease, should be conducted." Dr. Vasiliauskas reported on the pilot study findings of 12 patients treated during a 12-week study with low-dose (50-100 mg per day) Thalomid. In addition to this pilot study, other groups of researchers, including European and American investigative teams, are conducting trials using thalidomide to treat Crohn's disease. These groups reported results that are consistent with the Cedars-Sinai, Celgene-supported study during this meeting. There are approximately 200,000 people in the United States who have Crohn's disease, and approximately 5,000-10,000 new cases are diagnosed annually. Researchers have observed that Crohn's disease tends to run in families, and that the disease is most common in North America, Europe and Scandanavia, with a greater incidence of the disease in urban and northern environments. Thalidomide is contraindicated in pregnant women and women capable of becoming pregnant. Even a single capsule taken by a pregnant woman can cause severe birth defects or death to an unborn baby. The major adverse drug reactions known to be associated with thalidomide treatment include: peripheral neuropathy, a common, potentially severe side effect that may be irreversible; drowsiness/somnolence; dizziness/orthostatic hypotension; neutropenia; and increased HIV-viral load. Related Links: thalidomide, Celgene Corp.
|
